Risk factors
Nkarta (NKTX) risk factors
Item 1A of every Nkarta, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors93 risks3 new4 dropped9 reworded
Nkarta highlights new asset impairment charges from low stock prices, manufacturing scaling hurdles, and potential tariff impacts on single-source supplies.
Filed Mar 25, 2026 - FY2024 10-K risk factors94 risks
Nkarta develops novel, unproven CAR NK-cell therapies with no approved products and a history of significant operating losses. The company faces high clinical trial enrollment challenges, complex manufacturing requirements, and ongoing needs for additional capital.
Filed Mar 26, 2025